文献速递脑血管病

利用人类遗传学估计抑制凝血因子XI可达到的临床风险降低

Leveraging Human Genetics to Estimate Clinical Risk Reductions Achievable by Inhibiting Factor XI.
PubMed 文献 · Stroke · 2019-09-27

遗传倾向性降低FXI水平与静脉血栓和缺血性卒中风险降低相关,但与大出血无关。人类遗传学数据提示药物抑制FXI可能大幅降低缺血性卒中风险而无明确大出血风险增加。

要点

  • 遗传性降低FXI水平与静脉血栓风险降低相关(OR=0.1,95%CI 0.07-0.14)。
  • 遗传性降低FXI水平与缺血性卒中风险降低相关(OR=0.47,95%CI 0.36-0.61)。
  • 遗传性降低FXI水平与大出血风险无显著关联(OR=0.7,95%CI 0.45-1.04,P=0.0739)。

核心结论

  • 人类遗传学数据提示药物抑制FXI可能大幅降低缺血性卒中风险,而无明确大出血风险增加证据。

研究设计与样本

  • 研究分析两种改变FXI水平的常见遗传变异,组合为标准化遗传评分,对应活化部分凝血活酶时间相对增加30%。

主要发现

  • 遗传倾向性降低FXI水平与静脉血栓风险降低相关(OR=0.1,95%CI 0.07-0.14,P=3×10-43)。
  • 遗传倾向性降低FXI水平与缺血性卒中风险降低相关(OR=0.47,95%CI 0.36-0.61,P=2×10-8)。
  • 遗传倾向性降低FXI水平与大出血风险无显著关联(OR=0.7,95%CI 0.45-1.04,P=0.0739)。
  • 在高血栓风险亚组(如房颤患者)中,遗传性降低FXI水平带来的绝对风险降低更高。

临床怎么用

  • 遗传学证据支持FXI作为抗血栓治疗靶点,可能实现缺血性卒中风险降低而不显著增加大出血。
  • 该定量框架可用于支持估计药物调节FXI可达到的风险降低程度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background and Purpose- Coagulation factor XI (FXI) is a novel target for antithrombotic therapy addressed by various therapeutic modalities currently in clinical development. The expected magnitude of thrombotic event reduction mediated by targeting FXI is unclear. Methods- We analyzed the association of 2 common genetic variants, which alter levels of FXI, with a range of human phenotypes. We combined variants into a genetic score standardized to a 30% increase in relative activated partial thromboplastin time, equivalent to what can be achieved with pharmacological FXI reduction. Using data from 371 695 participants in the United Kingdom Biobank and 2 large-scale genome-wide association studies, we examined the effect of this FXI score on thrombotic and bleeding end points. Results- Genetic disposition to lower FXI levels was associated with reduced risks of venous thrombosis (odds ratio, 95% CI; P value; odds ratio=0.1, 0.07-0.14; P=3×10-43) and ischemic stroke (odds ratio=0.47, 0.36-0.61; P=2×10-8) but not with major bleeding (odds ratio=0.7, 0.45-1.04; P=0.0739). The observed relative risk reductions were consistent within a range of subgroups that were at high risk for thrombosis. Consistently, we observed higher absolute risk reductions conferred by genetically lower FXI levels in high-risk subgroups, such as patients with atrial fibrillation. Conclusions- Human genetic data suggest that pharmacological inhibition of FXI may achieve considerable reductions in ischemic stroke risk without clear evidence for an associated risk of major bleeding. The quantitative framework developed can be used to support the estimation of achievable risk reductions with pharmacological modulation of FXI.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Georgi B, Mielke J, Chaffin M, et al. Leveraging Human Genetics to Estimate Clinical Risk Reductions Achievable by Inhibiting Factor XI. Stroke. 2019. PMID: 31558144. doi:10.1161/STROKEAHA.119.026545

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。